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Development of second primary multiple 
myeloma five years after treatment for 
limited-stage small cell lung cancer: 
a rare case report
ABSTRACT 
Introduction. The development of a second primary malignancy (SPM) following small cell lung cancer (SCLC) 
has been previously reported in the literature. Especially smoking-related malignancy coupling is well known. The 
development of multiple myeloma (MM) in long-term survivors after treatment for SCLC is unknown. Here, we 
report the first case in the literature who developed MM 5 years after treatment for limited-stage SCLC.
Case report. A 67-year-old male patient was diagnosed with limited-stage SCLC. After he received chemotherapy 
and radiotherapy, he was followed up without medication. He was admitted to the hospital with back pain and dysp-
nea 5 years after the diagnosis of small cell lung cancer. MRI revealed osteolytic lesions in the vertebrae. Laboratory 
testing revealed a markedly elevated serum IgA and an elevated serum beta-2 microglobulin level. Serum immunofix-
ation revealed IgA lambda-type M-protein. Lambda excretion in urine immunofixation electrophoresis was observed. 
Bone marrow aspiration revealed the frequency of plasma cells to be 80% of all nucleated cells. Hence, the final 
diagnosis revealed IgA lambda free light chain MM. Treatment was given for multiple myeloma. In the follow-up, the 
patient experienced increased dyspnea and developed bilateral pleural effusion. The cytology sent from thoracente-
sis sampling was reported as plasmocyte-rich material. The patient fell into a coma and died in an intensive care unit. 
Conclusion. We presented the development of MM 5 years after treatment in a patient with SCLC who were 
treated for one year and then followed up with stable findings. It should be kept in mind that a patient with SCLC 
who is a long-term survivor and presents with back pain may have developed a primary malignancy originat-
ing from bone marrow rather than a bone metastasis. Patients should be advised smoking cessation after the 
treatment and diagnosis of SCLC. Also, the patients with SCLC who are long-term survivors should be closely 
monitored for the development of SPM.
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Introduction
Small cell lung cancer (SCLC) is a high-grade 
neuroendocrine tumor that represents about 15 per-
cent of all lung cancers. Nearly all patients with SCLC 
are current or former smokers [1]. Multiple myeloma 
(MM) is a hematologic malignancy characterized by the 
infiltration of bone and bone marrow with neoplastic 
plasma cells and the extensive presence of monoclonal 
Ig or light chains in serum or urine [2]. Second primary 
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malignancy (SPM) associated with smoking was found to 
be high in patients with lung cancer. The concomitance 
of a malignancy originating from plasma cells such as 
multiple myeloma and SCLC has not been described in 
the literature. In this case report, we present the devel-
opment of multiple myeloma following SCLC treatment.
Case presentation
A 67-year-old male patient was diagnosed with 
limited-stage SCLC in January 2012, proven by tho-
racic and abdomino-pelvic computed tomography 
(CT) scan and right supraclavicular lymphadenopathy 
biopsy. The patient had no history of other medical 
comorbidities. The patient had a smoking history of 
48 pack-years until the moment of diagnosis. He was 
treated with four cycles of cisplatin + etoposide com-
bination chemotherapy (cisplatin 80 mg/m2 intravenous 
(iv) infusion on D1, etoposide 100 mg/m2 iv infusion on 
D1–3, repeated every 3 weeks) along with concurrent 
thoracic radiotherapy. In July 2012, he was treated for 
nine weeks of weekly topotecan (4 mg/m2 iv infusion 
on D1, D8 and D15, repeated every 28 days) followed 
by six cycles of cyclophosphamide+doxorubicin+vin
cristin (cyclophosphamide 1000 mg/m2 iv infusion on 
D1, doxorubicin 40 mg/m2 iv infusion on D1, vincristine 
1 mg/m2 iv infusion on D1, repeated every 3 weeks) 
chemotherapy due to progression of lesions in the lung. 
After treatment, the lymph nodes in the cervical region 
disappeared, and the soft tissue mass in the right para-
tracheal area was markedly regressed in comparison 
with previous imaging. With these findings, the patient 
was monitored without drug treatment. There was no 
cigarette use during the one year when the patient 
received chemotherapy. However, he started to smoke 
again six months after the end of the treatment (one 
pack of cigarettes a day. In the last follow-up imaging 
performed in May 2017, the findings of stable disease 
were persisted. He was admitted to the Medical Oncol-
ogy Department with back pain and dyspnea in August 
2017. He had back pain for about two months and did 
not respond to painkillers. The physical examination 
revealed diffuse rhonchus in both lungs. Other vital signs 
and the physical examination were normal. Laboratory 
tests performed are displayed in Table 1. Bone marrow 
biopsy, serum protein electrophoresis and thoracic and 
lumbar magnetic resonance imaging (MRI) were done 
to rule out metastatic deposits in the patient and to know 
the cause of pancytopenia, hypercalcemia and elevated 
erythrocyte sedimentation rate (ESR). MRI revealed 
osteolytic lesions in the vertebrae (Fig. 1). Laboratory 
testing revealed a markedly elevated serum immuno-
globulin (Ig) A (IgA) level (59.3 g/L, reference range: 
0.7–4 g/L) and an elevated serum beta-2 microglobulin lev-
Table 1. Serum laboratory levels and protein electrophoresis
Parameter Level Normal range
WBCc 3.6 × 103/uL (4–10)
Neu 1.86 × 103/uL (1.5–7.3)
Hb 8,5 g/dL (12.1–17.2)
Plt 97 × 103/uL (150–400)
Sedimentation rate >140 mm/hour (0–20)
Ure 31 mg/dL (15–44)
Cre 1.17 mg/dL (0.72–1.25)
Na 142 mmol/L (136–145)
K 4.8 mmol/L (3.5–5.1)
Ca 11.47 mg/dL (8.4–10.2)
Total protein 7.8 mmol/L (3.5–5.1)
Albumin 2.2 g/dL (3.5–5)
The rates of protein electrophoresis
ALBUMIN 31.11% ( 55.8–65 )
ALFA1 4.37% ( 2.2–4.6 )
ALFA2 8.08% ( 8.2–12.5 )
BETA 22.40% ( 7.2–14.2 )
GAMA 34.04% ( 11.5–18.6 )
Figure 1. Sagittal magnetic resonance imaging with multiple 
bone osteolytic lesions of the cervical and thoracic spine
el (5.33 mg/L, reference range: 0.97–2.64 mg/L) (Tab. 2). 
Serum immunofixation revealed IgA lambda-type 
M-protein. Lambda excretion in urine immunofixation 
electrophoresis was observed. Bone marrow aspiration 
revealed the frequency of plasma cells to be 80% of 
all nucleated cells. Microscopic examination and flow 
cytometric analysis of bone marrow aspirate revealed 
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elevated numbers of CD38-positive abnormal plasma 
cells. In the bone marrow FISH analysis, 13q14.3 80% 
normal 20% number 13 chromosomal monosomy 
signals were observed, 25% CKS1B gene expression 
was increased. Also, p53 and Ig heavy chain (IgH)/ 
/breakapart were normal. Hence, the final diagnosis 
revealed IgA lambda free light chain MM. The patient 
was transferred to the hematology clinic and was treated 
with zoledronic acid (4 mg iv infusion) and one cycle of 
bortezomib plus cyclophosphamide plus dexametha-
sone (bortezomib 1.5 mg/m2 subcutaneously on D1, 8, 
15, 22, cyclophosphamide 300 mg/m2 orally on D1, 8, 
15, 22, dexamethasone 40 mg orally on D1, 18, 15, 22, 
repeated every 28 days) combination chemotherapy. 
In the follow-up, the patient experienced increased 
dyspnea and developed bilateral pleural effusion. The 
cytology sent from thoracentesis sampling was reported 
as plasmocyte rich material. The patient was admitted 
to the intensive care unit because of severe respiratory 
distress. The patient fell into a coma and died on the 
3rd day of admission to an intensive care unit.
Discussion
SCLC is an aggressive form of lung cancer character-
ized by rapid doubling time and high growth rate and 
early metastasis development and is strongly associated 
with smoking. The most important prognostic factor 
in patients with SCLC is the extent of disease (stage) 
at presentation. Although SCLC is highly responsive 
to both chemotherapy and radiotherapy, it commonly 
relapses within months despite treatment. For patients 
with the limited-stage disease, limited to the ipsilateral 
hemithorax and regional lymph nodes, median survivals 
range from 15 to 20 months, and the reported five-year 
survival rate is 10 to 13 percent. Patients with the 
limited-stage disease are primarily treated with a com-
bination of chemotherapy (cisplatin plus etoposide) 
and radiation therapy. SCLC has been rare in never 
smokers. Exposure to tobacco and multiple genetic 
defects including p53 mutations, loss of the retinoblas-
toma gene (RB1) function at 13q14, loss of PTEN, 
MYC amplification, activation of telomerase, and strong 
expression of cKit are related with oncogenesis in SCLC. 
However, mutations in the EGFR and KRAS oncogenes 
and p16 abnormalities are rare [3, 4].
MM is characterized by the neoplastic proliferation 
of plasma cells producing a monoclonal immunoglobu-
lin. Older age, immunosuppression, environmental 
exposures such as radiation, benzene, and other organic 
solvents including herbicides, and insecticides, and some 
primary (IgH chain translocations, trisomies) and sec-
ondary cytogenetic abnormalities (secondary IgH trans-
locations, deletion of 17p13 on p53 locus, Ras mutations, 
activation of NF kappa B) appear to play a major role 
in the development of MM [5, 6]. 
Careful monitoring for the development of SPM in 
patients with SCLC is necessary for long-term survivors, 
because the risk of developing SPM in these patients 
is significantly increased. The cessation of cigarette 
smoking after successful therapy is associated with 
a significantly decreased risk of an SPM [7]. The risk 
of SPM was increased by a number of chemotherapy 
cycles > 6, an age of > 60, treatment with combination 
chemotherapy, and chest irradiation [8, 9]. In a study 
including sixty-one patients who survived for more than 
two years, SPM was observed in seven patients (four with 
non-small cell lung cancer, two with gastric cancer, and 
one with prostate cancer) [10]. In another study includ-
ing forty-seven patients who were identified to be free of 
disease at two years, SPM was observed in 14 patients. In 
these patients, aerodigestive tract malignancies associ-
ated with smoking as SPM has been developed [11]. 
Also, in previous studies, the development of hemato-
logic malignancy as SPM in long-term survivors after 
treatment for SCLC has been reported. Hematologic 
malignancy developed in these patients was leukemia 
[12–15]. However, MM development as SPM in patients 
with SCLC has never been reported. To the best of our 
knowledge, this is the first reported case in the literature. 
The patient stopped smoking during the treatment for 
SCLC, but had started again six months after the end of 
the treatment. From the literature and past experience, 
we were expecting smoking-induced SPM development, 
but we were surprised by the development of MM in 
our patient. Because MM is not a smoking-related 
malignancy. We think that increased predisposition to 
MM development may relate to secondary effects of 
multimodality treatment including chemotherapy and 
radiotherapy. 
Conclusion
We presented the development of MM 5 years after 
treatment in a patient with SCLC who was treated for 
Table 2. Serum immunoglobulin levels
Parameter Level Normal range
Immunoglobulin G 1.53 g/L (7–16)
Immunoglobulin A 59.3 g/L (0.7–4)
Immunoglobulin M 0.186 g/L (0.4–2.3)
Lambda free light chain 62.2 mg/dL (8.3–27)
Kappa free light chain 9.29 mg/dL (6.7–22.4)
Free kappa to free lambda ratio 0.15 (0.26–1,65)
Beta 2 microglobulin 5.33 mg/L (0.97–2.64)
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one year and then followed up with stable findings. It 
should be kept in mind that a patient with SCLC who 
is a long-term survivor and presents with back pain may 
have developed a primary malignancy originating from 
bone marrow rather than a bone metastasis. Patients 
should be advised smoking cessation after the treat-
ment and diagnosis of SCLC. Also, the patients with 
SCLC who are long-term survivors should be closely 
monitored for the development of SPM.
Clinical Practice Points
Patients with long-term remission after being treated 
for small cell lung cancer must be close followed up for 
second primary cancers.
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